Quercetin

Evidence Anchor

BioHarmony 6.8/10

The 5.5 Neutral score reflects honest tension between a wide mechanistic story and a narrow band of replicated human signals. Quercetin earns its supplement shelf space for allergic rhinitis on phytosome, small BP reductions, chronic prostatitis support, and hyperuricemia adjuncts. It does not earn the senolytic, antiviral, MCAS, cancer, H pylori, or broad longevity language used in much of the marketing. The form matters more than the dose: phytosome and glucosylated forms outperform plain dihydrate by roughly 20 times. The most consequential risks are interaction-mediated and opportunity-cost-driven rather than intrinsic toxicity. ✅ Best for: Adults with seasonal or perennial allergic rhinitis trying quercetin phytosome 200 mg/day during exposure windows. Prehypertensive or stage 1 hypertensive adults adding 500 to 730 mg/day quercetin alongside diet, exercise, and clinical monitoring. Men with chronic prostatitis or chronic pelvic pain syndrome trialing 500 mg twice daily for 1 month under urology guidance. Adults with elevated uric acid or gout history considering a 4-week quercetin trial alongside the standard urate-lowering and dietary approach. Older inflamed adults curious about senolytic-class exposure who lack prescription access to dasatinib and accept that quercetin alone is not proven senolytic. ❌ Avoid if: Pregnant, trying to conceive, or breastfeeding without clinician oversight; pediatric users outside a clinician-directed allergy protocol. On warfarin, DOACs, antiplatelets, transplant drugs, chemotherapy, or narrow therapeutic index medications without explicit review. On statins handled by OATP1B1 (especially pravastatin) where interaction can raise plasma drug exposure. On dasatinib or other tyrosine kinase inhibitors outside a clinician-supervised senolytic protocol. Substituting quercetin for proven care in COVID, cancer, H pylori, MCAS, or serious infection. Planned surgery or dental procedure within 2 weeks. Buying generic liposomal quercetin products without product-specific human PK data when phytosome or EMIQ alternatives exist.

Read the full BioHarmony report

My score and my verdict: one signal of three, never the whole answer.